2008年至2015年期间新西兰的抗抑郁药处方情况。

Antidepressant prescribing in New Zealand between 2008 and 2015.

作者信息

Wilkinson Sam, Mulder Roger T

机构信息

House Officer, Neurology Department, Canterbury District Health Board, Christchurch.

Department of Psychological Medicine, University of Otago, Christchurch.

出版信息

N Z Med J. 2018 Nov 9;131(1485):52-59.

PMID:30408818

Abstract

AIM

To examine antidepressant prescribing trends in New Zealand adults from 2008-2015.

METHODS

Antidepressant prescribing data was sourced via the Ministry of Health. Data were examined by year, type of drug, ethnicity, gender, age and location of district health board.

RESULTS

All individuals dispensed an antidepressant in New Zealand were included. In 2015, 12.6% of all New Zealanders were prescribed an antidepressant (16% of females and 9% of males) an increase of 21% from 2008. The largest increase in drug classes were venlafaxine and tetracyclic antidepressants. The largest class of drugs prescribed were SSRIs, which made up 57% of the total. Europeans were the most likely to receive antidepressants at 15.7%, but increases were seen across all ethnic categories. The highest users were older European females at 22.8%.

CONCLUSIONS

Antidepressant prescribing rates continue to increase in New Zealand although this rate of increase is slowing. The highest users were European women, particularly those age 65 and older.

摘要

目的

研究2008年至2015年新西兰成年人抗抑郁药物的处方趋势。

方法

抗抑郁药物处方数据来自卫生部。数据按年份、药物类型、种族、性别、年龄和地区卫生委员会所在地进行分析。

结果

纳入了所有在新西兰配给过抗抑郁药物的个体。2015年，12.6%的新西兰人开具了抗抑郁药物处方（女性为16%，男性为9%），较2008年增长了21%。药物类别中增幅最大的是文拉法辛和四环类抗抑郁药。处方量最大的药物类别是选择性5-羟色胺再摄取抑制剂（SSRI），占总量的57%。欧洲人接受抗抑郁药物治疗的可能性最高，为15.7%，但所有种族类别均有增长。使用率最高的是65岁及以上的欧洲老年女性，为22.8%。